Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

20.06.25 23:45 Uhr

Werte in diesem Artikel

In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 1.03% at $26.01. The stock trailed the S&P 500, which registered a daily loss of 0.22%. Elsewhere, the Dow saw an upswing of 0.08%, while the tech-heavy Nasdaq depreciated by 0.51%. Prior to today's trading, shares of the company had lost 5.23% lagged the Medical sector's loss of 0% and the S&P 500's gain of 0.45%.Analysts and investors alike will be keeping a close eye on the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.44, indicating a 120% decline compared to the equivalent quarter last year. For the full year, the Zacks Consensus Estimates project earnings of -$1.86 per share and a revenue of $25 million, demonstrating changes of -84.16% and 0%, respectively, from the preceding year. It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Viking Therapeutics, Inc. presently features a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 87, positioning it in the top 36% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Viking Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Viking

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Viking

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Viking Therapeutics Inc

Wer­bung

Analysen zu Viking Therapeutics Inc

DatumRatingAnalyst
16.07.2019Viking Therapeutics OutperformOppenheimer & Co. Inc.
14.03.2019Viking Therapeutics BuyMaxim Group
12.12.2018Viking Therapeutics BuyB. Riley FBR
18.09.2018Viking Therapeutics BuyMaxim Group
18.09.2018Viking Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst
16.07.2019Viking Therapeutics OutperformOppenheimer & Co. Inc.
14.03.2019Viking Therapeutics BuyMaxim Group
12.12.2018Viking Therapeutics BuyB. Riley FBR
18.09.2018Viking Therapeutics BuyMaxim Group
18.09.2018Viking Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Viking Therapeutics Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen